People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Other Technology, Biotech / Pharma, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| T2 Biosystems, Inc. | — | Other Technology | Series D+ | $477.6M | $1.3B | 2010 |
| Seismic Therapeutic, Inc. | — | Biotech / Pharma | Series D+ | $146.3M | $1.9B | 2023 |
| Dare Bioscience, Inc. | — | Biotechnology | Series B | $102.0M | $93.7M | 2009 |
| Visterra, Inc. | — | Biotechnology | Series B | $82.4M | $1.4B | 2009 |
| Ocular Therapeutix, Inc | — | Biotechnology | Series B | $81.0M | $1.5B | 2013 |
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2013 |
| Seventh Sense Biosystems, Inc. | — | Biotechnology | Series B | $62.9M | $732.6M | 2011 |
| XTuit Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $39.5M | $748.7M | 2014 |
| Pandion Therapeutics, Inc. | — | Biotechnology | Series B | $21.6M | $857.3M | 2018 |
Alan Crane at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Crane on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 4 | 36 |
| Kevin Bitterman | 2 | 15 |
| Harry Wilcox | 2 | 6 |
| Ram Sasisekharan | 2 | 2 |
| DOUG LEVINSON | 2 | 2 |
| Jean-Francois Formela | 1 | 17 |
| Michael Greeley | 1 | 15 |
| FARHAD KHOSRAVI | 1 | 14 |
| Richard Lindstrom | 1 | 13 |
| John P Ryan | 1 | 11 |
| Brian Gallagher | 1 | 11 |
| Shelley Chu | 1 | 10 |
| David Mott | 1 | 9 |
| Brian Levy | 1 | 8 |
| Terry McGuire | 1 | 8 |
| Amarpreet Sawhney | 1 | 8 |
| Richard L Lindstrom | 1 | 8 |
| Carlo Rizzuto | 1 | 7 |
| Rajeev Dadoo | 1 | 7 |
| Robert Tepper | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.